, /PRNewswire/ -- EchoStar Corporation (NASDAQ: SATS) (the "Company") has notified holders of its 3.875% Convertible Senior Secured Notes due 2030 (the "Notes") that the Notes are convertible, at the option of the holders (the "Conversion Option") beginning on October 1, 2025, and ending at the close of business on December 31, 2025. The Notes are convertible into cash, shares of the Company's common stock or a combination thereof, at the Company's election. Any determination regarding the convertibility o ...

Core Viewpoint - Energy Fuels Inc. successfully closed an upsized offering of 0.75% Convertible Senior Notes due 2031, raising a total of US$700 million, reflecting strong investor confidence in the company's initiatives and strategies [1][3]. Offering Details - The offering consisted of 0.75% Convertible Senior Notes with a total principal amount of US$700 million, including an additional US$100 million purchased by initial investors [1]. - The notes will mature on November 1, 2031, unless converted, redeemed, or repurchased earlier [6]. - The cash interest coupon is set at 0.75% per annum, payable semi-annually starting May 1, 2026 [6]. Strategic Implications - The capital raised will strengthen the company's balance sheet and support the acceleration of its rare earth initiatives, including expansions at the White Mesa Mill and the Donald Project in Australia [3]. - The company believes the convertible notes offer a favorable alternative to traditional debt financing due to their attractive coupon rate [2]. Conversion and Dilution Management - The conversion price for the notes is approximately $20.34 per common share, representing a 32.5% premium over the last reported sale price [6]. - The effective conversion price was increased to $30.70 through the purchase of capped call options, which cost approximately $53.55 million [6]. - Conversions may be settled in common shares, cash, or a combination of both, at the company's discretion [6].

- NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES - VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- South Star Battery Metals Corp. (“South Star” or the “Company”) (TSXV: STS) (OTCQB: STSBF), is pleased to announce a non-brokered private placement of units (the “Units”) for gross proceeds of up to C$4.17 million (US$3.0 million) (the “Unit Offering”) and a concurrent non-brokered private placement of unsecured convertible notes (the “Notes”) for gross proceeds of ...

Core Viewpoint - Mesoblast Limited has announced a plan to issue up to US$50 million in unsecured convertible notes to support its capital structure and ongoing pipeline growth opportunities, subject to shareholder approval [1][2]. Group 1: Convertible Notes Details - The company may issue the convertible notes in tranches of US$10 million, with a maturity date of 5 years after the first issuance [2]. - The conversion price is set at US$16.25 per ADR, which is a 126% premium over the last closing price on Nasdaq and a 29% premium on the ASX [3]. - The notes will carry a coupon of 5% per annum on the face value [3]. Group 2: Investor Considerations - Investors will receive a commitment fee of US$100,000 and warrants for 2 million ordinary shares upon entering the agreement, with additional warrants for 3 million shares if the option is exercised [4]. - The warrants will have the same exercise price as the conversion price and a maturity date of 4 years from the issuance date [4]. Group 3: Company Overview - Mesoblast is a leader in developing allogeneic cellular medicines for severe inflammatory conditions, utilizing a proprietary mesenchymal lineage cell therapy technology platform [6]. - The company has FDA-approved therapies, including Ryoncil for treating steroid-refractory acute graft versus host disease in pediatric patients [7]. - Mesoblast is also developing additional therapies for various inflammatory diseases and has established commercial partnerships in multiple regions [8]. Group 4: Intellectual Property and Manufacturing - Mesoblast holds over 1,000 granted patents or applications related to its cell therapy technologies, providing commercial protection expected to last until at least 2041 in major markets [9]. - The company has proprietary manufacturing processes that yield industrial-scale, cryopreserved cellular medicines, ensuring availability to patients worldwide [10].

💥BREAKING:COINBASE PLANS TO RAISE $2,000,000,000 THROUGH CONVERTIBLE NOTES. https://t.co/tj0t3qmfus ...

⚡️NEW: Coinbase plans to raise $2B through convertible notes.Proceeds will help offset dilution and support tech, operations, and potential acquisitions. https://t.co/HjkrNEk2BQ ...

Core Insights - OSR Holdings, Inc. provided a transparency update regarding its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund, emphasizing that future issuances are not purely dilutive and will support business development [1][3]. Financing and Share Issuance - The company has issued a total of 2,308,382 shares under structured financing, with less than 10% of registered shares utilized under the ELOC agreement [7]. - The registered share capacity under the ELOC agreement is 9,500,000, with 767,500 shares issued since June 17, 2025 [7]. Business Development and Partnerships - Proceeds from financing are being invested in drug R&D, medical device initiatives, and digital asset ecosystems, with a focus on protecting shareholder value [3]. - The Woori IO clinical trial in Korea is being conducted in partnership with a major technology company in mobile and wearable devices, with further details expected after the Stock Purchase Agreement is signed [4]. Company Overview - OSR Holdings, Inc. is dedicated to advancing biomedical innovation in health and wellness, focusing on immuno-oncology, regenerative biologics, and medical device distribution [5]. - The company aims to improve patient care through cutting-edge research and development [5]. Strategic Initiatives - The company is pursuing a "Plug-and-Play" bacterial vector platform for cancer immunotherapy and a Disease-Modifying Osteoarthritis Drug (DMOAD) candidate [8]. - A strategic move is underway to acquire noninvasive glucose monitoring technology through a signed term sheet with Woori IO [8].

Core Viewpoint - Upexi, Inc. has successfully closed a private placement convertible note offering, raising approximately $150 million, alongside a previously disclosed $50 million equity offering, resulting in total gross proceeds of around $200 million before expenses [1][2]. Group 1: Note Offering Details - The convertible notes have an interest rate of 2.0% payable quarterly, a fixed conversion price of $4.25 per share, and a maturity period of 24 months [2]. - The notes are collateralized by Solana (SOL) provided by the holders, and the SOL acquired will be part of the Company's treasury [2][3]. - Big Brain Holdings acted as the lead investor in the note offering, contributing to the increase of the Company's SOL holdings from approximately 735,692 to 1.65 million SOL [3]. Group 2: Financial Impact - The total gross proceeds from the note offering and the equity offering amount to approximately $200 million before deducting placement agent fees and other expenses [2]. - The Company has diversified its asset management strategy by entering the cryptocurrency space, indicating a strategic shift in its financial operations [6]. Group 3: Company Overview - Upexi, Inc. specializes in the development, manufacturing, and distribution of consumer products and has expanded into the cryptocurrency industry [6].

Core Viewpoint - DeFi Development Corp. has announced a private offering of $112.5 million in convertible senior notes, aimed at accumulating and compounding Solana (SOL) as part of its treasury strategy [1][13]. Group 1: Transaction Details - The offering includes an option for initial purchasers to buy an additional $25 million in convertible notes within a 7-day period after the initial issuance [2]. - The offering is expected to close on July 8, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - The estimated net proceeds from the offering will be approximately $108.1 million, or about $132.2 million if the additional notes option is fully exercised [3]. - Approximately $75.6 million of the net proceeds will be used for a prepaid forward stock purchase transaction, with the remainder allocated for general corporate purposes, including the acquisition of SOL [3]. Group 3: Convertible Notes Details - The convertible notes will have a 5.5% annual interest rate, payable semi-annually, and will mature on July 1, 2030 [4]. - The initial conversion rate is set at 43.2694 shares per $1,000 principal amount, equating to an initial conversion price of approximately $23.11 per share, representing a 10% premium over the closing price of $21.01 on July 1, 2025 [5][7]. Group 4: Prepaid Forward Stock Purchase Transaction - The company has entered into a prepaid forward stock purchase transaction valued at approximately $75.6 million, initially covering about 3.6 million shares of common stock [9]. - This transaction is designed to facilitate derivative transactions, allowing investors to hedge their investments in the convertible notes [10]. Group 5: Company Overview - DeFi Development Corp. focuses on accumulating SOL as its primary treasury asset, providing investors with direct exposure to the Solana ecosystem [13]. - The company also operates its own validator infrastructure and engages in decentralized finance (DeFi) opportunities, while offering an AI-powered platform for the commercial real estate industry [13].

Core Viewpoint - Opendoor Technologies Inc. has successfully completed a transaction involving the exchange of its 2026 Convertible Senior Notes for new 2030 Convertible Senior Notes, raising $325 million in total, which includes $75.3 million in cash to strengthen its balance sheet and support its mission in the residential real estate market [1][2]. Group 1: Transaction Details - The company issued $325 million in 2030 Convertible Senior Notes, which includes approximately $245.8 million exchanged for 2026 Notes and $79.2 million raised in cash [1]. - The 2030 Notes have a 7.000% annual interest rate and will mature on May 15, 2030, unless converted or repurchased earlier [2][3]. - The gross proceeds from the cash subscription are expected to be around $75.3 million, intended for general corporate purposes [2]. Group 2: Conversion and Redemption Features - The initial conversion rate for the 2030 Notes is set at 637.1050 shares of common stock per $1,000 principal amount, equating to an initial conversion price of approximately $1.57 per share, representing an 80% premium over the last reported share price of $0.872 [4]. - Holders of the 2030 Notes can require the company to repurchase their notes at 100% of the principal amount upon a fundamental change [5]. - The company can redeem the 2030 Notes starting May 22, 2028, if the stock price exceeds 130% of the conversion price for a specified period [5]. Group 3: Advisory and Additional Information - J. Wood Capital Advisors LLC acted as the advisor for the transaction [6]. - For further details regarding the transaction, the company has filed a Current Report on Form 8-K with the SEC [6].